Antibacterial activity of moxifloxacin on bacteria associated with periodontitis within a biofilm.
The activity of moxifloxacin was compared with ofloxacin and doxycycline against bacteria associated with periodontitis within a biofilm (single strain and mixed population) in vitro. MICs and minimal bactericidal concentrations (MBCs) of moxifloxacin, ofloxacin and doxycyline were determined against single strains and mixed populations in a planktonic state. Single-species biofilms of two Porphyromonas gingivalis and two Aggregatibacter actinomycetemcomitans strains and a multispecies biofilm consisting of 12 species were formed for 3 days. The minimal biofilm eradication concentrations (MBECs) were determined after exposing the biofilms to the antibacterials (0.002-512 µg ml(-1)) for 18 h, addition of nutrient broth for 3 days and subsequent subcultivation. Photographs were taken using confocal laser-scanning microscopy and scanning electron microscopy. The MICs and MBCs did not differ between ofloxacin and moxifloxacin against A. actinomycetemcomitans, whilst moxifloxacin was more active than the other tested antibacterials against anaerobes and the mixed population. The single-species biofilms were eradicated by moderate concentrations of the antibacterials, and the lowest MBECs were always found for moxifloxacin (2-8 µg ml(-1)). MBECs against the multispecies biofilms were 128, >512 and >512 µg ml(-1) for moxifloxacin, ofloxacin and doxycycline, respectively. In summary, moxifloxacin in a topical formulation may have potential as an adjunct to mechanical removal of the biofilms.
School of Dental Medicine, Department of Periodontology, University of Bern, Bern, Switzerland.
Phoebus
P
Tsaousoglou
Department of Electron Microscopy, University Hospital of Jena, Jena, Germany.
Sandor
S
Nietzsche
Department of Restorative and Preventive Dentistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Georg
G
Cachovan
School of Dental Medicine, Department of Periodontology, University of Bern, Bern, Switzerland.
Anton
A
Sculean
School of Dental Medicine, Department of Periodontology, University of Bern, Bern, Switzerland.
Sigrun
S
Eick
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification*; D018407:Bacterial Physiological Phenomena; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D004318:Doxycycline / Q000494:pharmacology; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000494:pharmacology; D010518:Periodontitis / Q000382:microbiology*; D011804:Quinolines / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D015242:Ofloxacin; D004318:Doxycycline; D000077266:Moxifloxacin